ABCC8 rs7571542: Type 2 Diabetes Risk and Sulfonylurea Response
The rs7571542 single nucleotide polymorphism is a missense variant located within the ABCC8 gene, which encodes the sulfonylurea receptor 1 (SUR1) subunit of pancreatic beta-cell potassium channels. Carrying this variation produces an amino acid change (p.Ala1369Ser) that has been evaluated in population studies for modest shifts in type 2 diabetes risk and response to sulfonylurea medications. Because observed effect sizes are small and tightly linked to neighboring variants, its clinical relevance remains nuanced and classified with limited evidence.
What each genotype means
Typical ABCC8 variant profile
This genotype represents the common form of the ABCC8 gene at this position. Research into this variant, which results in an amino acid change (p.Ala1369Ser), has explored its potential role in insulin secretion and type 2 diabetes risk, though findings remain mixed and often show limited clinical impact. You should discuss any concerns regarding diabetes risk or medication response with your healthcare provider.
This is a common genotype, with the minor allele frequency for the variant being approximately 0.35-0.40 in European populations.
Heterozygous ABCC8 variant profile
Carrying one copy of the variant allele means your genetic profile at this location is different from the most common form. While some studies have investigated whether this variant influences insulin secretion or the effectiveness of sulfonylurea medications, the evidence is inconsistent and currently considered limited. Please consult your clinician or pharmacist if you are prescribed sulfonylurea medications to discuss how your individual profile might relate to treatment efficacy.
This genotype is frequently observed, as the minor allele is present in roughly 35-40% of European populations.
Variant ABCC8 genotype
This genotype indicates you carry two copies of the variant allele at this position. Scientific literature has examined this variant for potential associations with type 2 diabetes risk and response to sulfonylurea drugs, but results are conflicting and the clinical significance remains uncertain. Always discuss your specific health history and any medication dosing with your doctor or pharmacist.
This genotype is less common than the others, occurring in a significant portion of the population consistent with a minor allele frequency of approximately 0.35-0.40 in European ancestry groups.
Genetic Location and Molecular Biology
The rs7571542 variant is situated in the ABCC8 gene, positioned on the short arm of chromosome 11. ABCC8 provides instructions for assembling the sulfonylurea receptor 1 (SUR1) protein, a regulatory subunit of the ATP-sensitive potassium (KATP) channel expressed primarily in pancreatic beta cells. These channels play an indispensable role in maintaining glucose homeostasis by coupling cellular energy production to insulin secretion. At the genomic level, rs7571542 corresponds to an exchange of guanine for adenine or thymine depending on genomic strand reporting, commonly resulting in an alanine-to-serine amino acid substitution at position 1369 (p.Ala1369Ser). This subtle structural change occurs within a conserved region of the receptor, potentially altering the channel's sensitivity to intracellular ATP/ADP ratios and changing how potassium currents regulate cell depolarization.
Biological Role of the ABCC8 Gene
Under resting conditions, pancreatic beta cells maintain open KATP channels, which stabilizes cell polarization and prevents spontaneous insulin exocytosis. When blood glucose concentrations rise, intracellular glucose metabolism generates adenosine triphosphate (ATP), leading to the closure of these KATP channels. This closure causes cellular depolarization, opening voltage-gated calcium channels and stimulating the rapid exocytosis of insulin granules into the bloodstream. Pathogenic mutations in ABCC8 that disrupt channel opening or closing cause monogenic conditions such as congenital hyperinsulinism or neonatal diabetes. For common variants like rs7571542, the protein alteration produces far less dramatic functional consequences, subtly tuning insulin release dynamics rather than completely disabling the channel.
Association with Diabetes and Sulfonylurea Response
Decades of genetic epidemiological studies have examined rs7571542 for potential associations with type 2 diabetes susceptibility and variability in antidiabetic medication efficacy. The variant is in strong linkage disequilibrium with other well-studied variants in the adjacent KCNJ11-ABCC8 locus, particularly KCNJ11 p.Glu23Lys (rs5219). Some pharmacogenetic investigations suggest that individuals harboring the minor allele may exhibit modest alterations in glycemic response when treated with sulfonylurea medications, which stimulate insulin secretion by directly binding SUR1. However, findings across diverse cohorts have presented mixed results, and overall evidence strength remains limited. Major clinical guidelines do not recommend altering medication regimens solely based on rs7571542 status, as lifestyle, diet, baseline glycemia, and renal function exert far greater clinical influence.
Population Patterns and Linkage Disequilibrium
The frequency of rs7571542 alleles varies significantly across global populations, reflecting distinct ancestral evolutionary histories. In European reference cohorts, the minor allele demonstrates a frequency typically estimated between 0.35 and 0.40, indicating that both heterozygous and homozygous variant genotypes are common in these groups. Frequencies can vary moderately across East Asian, African, and South Asian populations. Because rs7571542 is inherited within a tightly co-segregating block of variation encompassing both ABCC8 and KCNJ11, researchers frequently emphasize that observed trait associations may reflect the collective impact of the entire regional haplotype rather than rs7571542 acting independently.
Navigating Your Genetic Data Responsibly
Discovering an alternate genotype at rs7571542 on a consumer genetic report provides an educational window into your biological makeup, but it is not a clinical diagnosis. This variant does not cause diabetes on its own, nor does it guarantee an adverse or diminished reaction to antidiabetic therapies. Blood sugar regulation is governed by hundreds of polygenic risk loci along with vital environmental and lifestyle factors, including physical activity, diet, and sleep. You should never initiate, discontinue, or modify prescription medications, such as sulfonylureas or metformin, based on direct-to-consumer genetic findings. Any concerns regarding metabolic health or medication safety should be discussed with a physician, endocrinologist, or clinical pharmacist.
How common is this variant?
The minor allele for rs7571542 occurs at a frequency of approximately 0.35 to 0.40 in populations of European ancestry, with varying frequencies observed across other global ancestral groups.
Frequently asked questions
What is the rs7571542 variant in ABCC8?
The rs7571542 variant is a common single nucleotide polymorphism in the ABCC8 gene that results in an amino acid substitution (p.Ala1369Ser) in the sulfonylurea receptor 1 protein. This protein helps regulate potassium flow and insulin release in pancreatic beta cells.
Does having the rs7571542 variant mean I will get type 2 diabetes?
No, carrying this variant does not mean you will develop type 2 diabetes. While some studies report a small statistical association, the variant's individual effect size is very modest and operates alongside hundreds of other genetic factors and lifestyle choices.
How does rs7571542 affect sulfonylurea diabetes medications?
Because the ABCC8 protein is the molecular target for sulfonylurea drugs, researchers have investigated whether rs7571542 modifies drug efficacy or hypoglycemia risk. While minor pharmacodynamic differences have been reported in research settings, evidence remains mixed, and treatment choices should always be guided by your healthcare provider.
Is rs7571542 related to monogenic neonatal diabetes or MODY?
While rare, severe mutations in ABCC8 can cause neonatal diabetes or maturity-onset diabetes of the young (MODY12), rs7571542 is a common polymorphism with subtle physiological effects. It is distinct from the rare high-impact mutations that cause monogenic endocrine disorders.
Should I change my diabetes medication based on my rs7571542 result?
No, you should never adjust, stop, or start diabetes treatments based on commercial genetic testing. Always review medication response, dosing, and therapeutic options with your clinician or pharmacist.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7571542?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ABCC8
This variant in the ABCC8 gene is associated with hyperinsulinemic hypoglycemia and is frequently documented in clinical databases.
Variants in the ABCC8 gene are linked to insulin secretion regulation, which is critical for maintaining hormonal balance during pregnancy.
This variant in the ABCC8 gene is documented in clinical databases and is relevant for assessing carrier status for certain metabolic conditions.